Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + tislelizumab versus pembrolizumab in first-line PD-L1-high advanced NSCLC
CTR20211464Phase 3Terminated
- Sponsor
- BeOne Medicines
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ociperlimab, tislelizumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by BeOne Medicines. Started Jul 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211464.